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CASE REPORT
A woman with forgetfulness and falls
Louise Pealing general practitioner, Steve Iliffe professor of primary care for older people
Research Department of Primary Care and Population Health, Royal Free Hospital, London NW3 2PF, UK
A 69 year old woman presented to her general practitioner with
a six month history of occasional falls and fluctuating
forgetfulness and attention. Although she reported no difficulties
with names and dates she needed help with taking drugs and
preparing meals. She had also had two episodes of apparent
visual hallucinations of a woman standing at the foot of her bed.
Her sleep behaviour had been poor for many years, with frequent
strong physical jerks and motion while sleeping. She had no
symptoms of altered or lowmood. Her medical history included
hypothyroidism, osteoporosis, and cholesteatoma, and she was
being investigated for a mixed fibre peripheral sensory
neuropathy of unknown cause. Current drugs included
levothyroxine, calcitriol, calcium carbonate-colecalciferol, and
lansoprazole. She did not drink alcohol and was a non-smoker.
On examination she was fully orientated in time and place and
her AMTS (abbreviated mental test score) was 10/10 with an
MMSE (mini-mental state examination) score of 26/30. Her
blood pressure, temperature, and cardiovascular and respiratory
examinations were normal. Cranial nerve examination was
normal with no primitive reflexes or supranuclear gaze palsy.
Tone and power were normal throughout all limbs, as were
sensation and reflexes in the upper limbs. The lower limbs
showed reduced vibration and pin prick sensation to themid-shin
bilaterally, and joint position sense was limited to large
movements. She showed no evidence of bradykinesia or apraxia,
but her gait was ataxic in keeping with her peripheral sensory
impairment.
Questions
1 What is the differential diagnosis?
2 What investigations would you do?
3 How should this patient be managed?
Answers
1 What is the differential diagnosis?
Short answer
Given the patient’s fluctuating forgetfulness and alertness, the
differential diagnosis must include causes of delirium and
dementia. The most common causes of delirium in this age
group are infection, metabolic and nutritional disturbances
(including hypoxia and hypoglycaemia), cerebral haematomas
caused by trauma, intoxication, endocrinopathies (including
thyroid and parathyroid disorders), space occupying lesions,
and side effects or interactions of drugs. The syndrome of
dementia has four main types: Alzheimer’s disease, vascular
dementia, dementia with Lewy bodies, and frontotemporal
dementia. A corroborative history from a family member or
carer is essential when making a diagnosis.1
Long answer
To differentiate between delirium or dementia as causes of our
patient’s symptoms, it is important to clarify whether the onset
of symptoms was gradual, acute, or fluctuating. These two
syndromes can also be distinguished between on the basis of
changes in consciousness, attention, and psychomotor activity,
all of which tend to be disturbed or fluctuating in delirium but
minimally affected in dementia,2 although they are common in
dementia with Lewy bodies. The simple CAM tool (confusion
assessment method) can be used to screen for delirium and is
easily administered within a general practice consultation,
although it also needs a supporting history.3 The tool identifies
an acute onset and fluctuating course, inattention, disorganised
thinking, and an altered level of consciousness. A diagnosis of
delirium requires the first two criteria and either the third or
fourth. The diagnosis is complicated by the strongest risk factor
for delirium being dementia, with a fivefold increase in risk of
delirium in patients with dementia.4
Common infective causes of delirium in older people include
pneumonia and urinary tract infection,5 which can present
atypically in older people.6 Fluctuating cognitive effects can be
caused by hypoglycaemia as a result of poorly controlled
diabetes or insulinomas,7 although these tumours are relatively
rare. Hyperparathyroidism can also present with a mixed picture
of fluctuating symptoms associated with diurnal variation but
on a background of gradual decline.8 Common drugs that can
cause delirium include anticholinergic drugs, anticonvulsants,
antidepressants, antipsychotics, antiparkinsonian agents, opioid
analgesics, and sedatives, in addition to multipharmacy.9
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The most likely cause of this patient’s protracted symptoms of
forgetfulness is a dementia syndrome. Dementia is characterised
by a progressive decline that causes memory loss and
impairment in at least one other cognitive function, such as
recognition, language, speech, or higher executive functions
that affect activities of daily living.10 The prevalence of the
various subtypes of dementia is unclear, but nearly two thirds
(62%) of patients with dementia in the United Kingdom are
thought to have Alzheimer’s disease and around a quarter (27%)
to have vascular dementia or mixed Alzheimer’s disease and
vascular dementia pathology.11 Most of the remainder (around
8%) have dementia with Lewy bodies, frontotemporal,
Parkinson’s disease dementia, and alcoholic dementia in
decreasing frequency.11
Our patient’s symptoms were most typical of dementia with
Lewy bodies—her cognitive symptoms fluctuated, often on an
hourly basis, and included visual hallucinations. She also had
supporting features of frequent falls and rapid eye movement
sleep behaviour disorder (characterised by complex motor
activity during rapid eye movement sleep).12 13 Dementia with
Lewy bodies—first described in 1990—has symptoms similar
to both Alzheimer’s disease and Parkinson’s disease, but the
parkinsonian motor features present after the cognitive
symptoms.14Dementia with Lewy bodies, idiopathic Parkinson’s
disease, and Parkinson’s disease dementia are different but
overlapping phenotypes, and it is unclear whether they are
distinct but convergent clinical syndromes or divergent common
neurobiological pathologies. Memory impairment occurs later
in dementia with Lewy bodies and is less pronounced than in
Alzheimer’s dementia, although both dementia subtypes seem
to have a similar rate of progression.15 It is important to
distinguish between these two types of dementia because the
clinical progression can be different and patients with dementia
with Lewy bodies are exquisitely sensitive to neuroleptic drugs,
with 50-80% having side effects such as confusion, sedation,
rigidity, and most importantly increased mortality.16 17
2 What investigations would you do?
Short answer
No simple blood test is available to screen for dementia. Blood
tests are important in helping to rule out delirium but are also
used in the investigation of dementia—to look for reversible
causes of dementia—and specialist memory clinics should
undertake full neuropsychological profiling along with
appropriate brain imaging.
Long answer
Investigations appropriate to primary care should include a
screen for risk factors such as diabetes and
hypercholesterolaemia that might contribute to a vascular
component of dementia. Commonly requested blood tests
include a full blood count; renal and liver profile; thyroid
function; and concentrations of calcium, vitamin B12, folate,
fasting glucose, and cholesterol. Urinalysis should be performed
to screen for infection as a cause of delirium.
Electrocardiography and chest radiography are also advised by
the UK guidelines.1 In addition, if the history or physical
examination point to specific risk factors, request HIV, syphilis,
and Borrelia serology blood tests.
Several cognitive screening tests are available for use in primary
care. The most well known is the MMSE.18 However, this test
is difficult to administer in the short time allowed for general
practice consultations and it may show cultural and language
bias.19Newer screening tests have been developed and validated
for use in the community setting. They have been shown to be
as robust as the MMSE but can be administered in five minutes
or less; these tests include the general practitioner assessment
of cognition (GPCOG), mini-cog, and memory impairment
screen, with sensitivity varying from 69% to 80% and specificity
from 86% to 96%.20Another screening tool, the 6 item cognitive
impairment test (6CIT) has also been shown to be at least
equivocal to theMMSE in selected secondary care populations.21
GPCOG (www.gpcog.com.au/prep.php) and 6CIT (www.
falklandsurgery.co.uk/6cit/index.asp) are available electronically
for ease of administration in the surgery. Most cognitive
screening tools are developed for typical symptoms of
Alzheimer’s disease, and patients with dementia with Lewy
bodies may fall within the normal range. These screening tests
are used to help decide on the need for referral to a specialist
memory clinic for more thorough cognitive and
neuropsychological assessment, including structural
neuroimaging. When a diagnosis of dementia is suspected, this
possibility must be discussed candidly and sensitively with the
patient and carer to gauge their expectations and wishes before
making a referral to specialist services.22
The battery of specific tests included in neuropsychological
testing varies by clinic and also depends on the type of dementia
and cognitive and functional disturbances that are suspected.
Patients with dementia with Lewy bodies usually show
prominent early impairment in attention, visuospatial skills, and
visuoconstructive skills—as detected by clock drawing and
figure copying tests—whereas those with Alzheimer’s dementia
show greater impairments in memory.12
Structural and physiological neuroimaging are increasingly
being used to aid earlier distinction between dementia with
Lewy bodies and Alzheimer’s disease. Computed tomography
and magnetic resonance imaging tend to show more advanced
hippocampal and mediotemporal lobe atrophy in Alzheimer’s
disease than in dementia with Lewy bodies, but this is not
specific, especially in early disease.13 The dopaminergic system
can be physiologically imaged using single photon emission
computed tomography (SPECT) and positron emission
tomography (PET) and the ligands FP-CIT labelled with
iodine-123 (N-fluropropyl-2bcarbomethoxy-3b-4-123I-iodophenyl
tropane) and dopa labelled with fluorine-18 (18F-flurodopa),
respectively. Lewy bodies cause disruption of the presynaptic
dopaminergic neurones in the corpus striata, as shown by
reduced ligand uptake in these areas with SPECT. Ongoing
multicentre trials are assessing the concordance between clinical
diagnoses, SPECT neuroimaging diagnoses, and postmortem
diagnoses for dementia with Lewy bodies.23-25 PET is used much
less often in clinical practice, but group studies have shown
good discrimination between dementia with Lewy bodies and
Alzheimer’s disease, with occipital hypoperfusion being seen
in dementia with Lewy bodies26-29; one group has suggested that
occipital hypoperfusion may be responsible for the visual
hallucinations in this condition.29Guidelines now reflect the use
of neuroimaging in early diagnosis and it is no longer necessary
to have two core clinical features of dementia with Lewy bodies,
but instead one core clinical feature with supportive
neuroimaging can be used to make a probable diagnosis (box).
Some clinics also perform analysis of cerebrospinal fluid to
look for Creutzfeldt-Jakob disease and to search for specific tau
and amyloid β proteins seen in Alzheimer’s disease. More
recently, cardiac imaging with 123I labelled
meta-iodobenzylguanidine (123I-MIBG) has shown a reduction
in autonomic postganglionic sympathetic fibres in the cardiac
plexus in Lewy body degenerative diseases, such as dementia
with Lewy bodies and idiopathic Parkinson’s disease. This test
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Revised criteria for the diagnosis of dementia with Lewy bodies12
Core features*
Fluctuating cognition with pronounced variations in attention and alertness
Recurrent visual hallucinations that are typically well formed and detailed
Spontaneous features of parkinsonism
Suggestive features†
Low dopamine transporter uptake in the basal ganglia demonstrated by single photon emission computed tomography and positron
emission tomography
Severe neuroleptic sensitivity
Rapid eye movement sleep behavioural disorder
*Two core features needed for a probable diagnosis in a cognitively impaired patient, one for a possible diagnosis
†One core feature plus one or more suggestive features in a cognitively impaired patient sufficient to make a probable
diagnosis
has been used to discriminate between Alzheimer’s disease and
dementia with Lewy bodies in people with moderate
dementia.30-32 These changes may support the early diagnosis
of dementia with Lewy bodies, but they lack specificity because
reduced uptake on MIBG scans is also seen in cardiovascular
diseases that are common in this typically older age group, such
as ischaemic heart disease, cardiomyopathy, and their risk factor,
diabetes.13
A postmortem brain biopsy is needed for a definitive diagnosis,
with cortical or brainstem Lewy body pathology being essential
criteria.33 Other changes are also common, such as Alzheimer’s
pathology and spongiform pathology.33 Lewy bodies are
accumulations of α synuclein protein that form strongly
eosinophilic intracytoplasmic neuronal inclusions. As with
Alzheimer’s disease, these protein accumulations are thought
to be associated with the clinical symptoms of Lewy body
diseases through neuronal cell loss and disruption of normal
brain architecture.
3 How should this patient be managed?
Short answer
After baseline investigations in primary care, we referred our
patient to local specialist memory services for neuroimaging,
neuropsychological assessment, and consideration of
pharmacotherapy. A thorough assessment of current needs and
future goals should be made with the patient and carers, and
appropriate referral should be made to members of the
multidisciplinary care team, with planned regular review.
Long answer
UKdementia clinical guidelines from 2006 describe overarching
priorities of care for patients with dementia that should guide
decision making between patients, carers, and health and social
care practitioners.1 The recommendations include
non-discrimination; seeking valid consent using the provisions
of the Mental Capacity Act 200534; assessing and providing for
the needs of carers; integrating health and social care; providing
specialist memory services for all people with a possible
diagnosis of dementia; and comprehensively assessing and
managing non-cognitive and behavioural symptoms that can
distress patients and carers. The Department of Health built on
this guidance with its National Dementia Strategy (2009),35 and
most recently with its publication of risk guidance for dementia
(2010) to maintain function and to promote and support personal
freedoms and independent living in people with dementia.36
Patients and carers should have early signposting to support
groups such as the Alzheimer’s Society (http://alzheimers.org.
uk/), Lewy Body Dementia Association (www.lbda.org/), the
Lewy Body Society (www.lewybody.co.uk/), Dementia UK
(www.dementiauk.org/), and MIND.37 Carers of patients with
dementia will need support—such as psychological services,
support groups, and respite care—to help them in their role.
Planning should be encouraged, particularly with regard to
advocacy, decisions on medical treatment that may include
advanced statements; living arrangements; and finances,
including appointing a lasting power of attorney. The guiding
theme of all management decisions taken with the patient and
carers should be one of supporting and maintaining the patient’s
independence and quality of life.
Specialist memory services are primarily responsible for
balancing the treatment of the many facets of this clinical
syndrome—cognitive, behavioural, psychiatric, mood related,
and extrapyramidal. First line drugs for cognitive and psychiatric
symptoms are the cholinesterase inhibitors—donepezil,
galantamine, and rivastigmine—which rarely exacerbate the
associated extrapyramidal symptoms; rivastigmine has the most
supportive data for this indication.18 38-40 Treat parkinsonian
motor features with dopaminergic agents, commonly carbidopa
and levodopa, and titrate them to the optimum dose to balance
any improvement in motor function against possible worsening
of cognitive and psychiatric symptoms.38Depression is common
in dementia with Lewy bodies and despite the lack of clinical
trials assessing the efficacy of antidepressants in this group,
selective serotonin reuptake inhibitors are advised as first line
agents, with avoidance of tricyclic antidepressants in case of
antimuscarinic side effects.38 41 42 The management of psychotic
symptoms, such as visual hallucinations and delusions that can
lead to pronounced agitation, are particularly challenging.
Patients with Lewy body dementia have marked neuroleptic
sensitivity, with increased morbidity and mortality,43 44 which
abrogates the use of typical antipsychotics. Non-pharmacological
methods should be instituted first, and only in the case of severe
and recalcitrant symptoms should specialist teams consider
small doses of the atypical antipsychotics; clozapine has been
consistently more effective than quetiapine for this indication.41
Patient outcome
Our patient developed symptoms of depression andwas followed
up jointly by the local neurology and memory services and
mental health teams for older people. She was givenmirtazapine
for depressive symptoms and the cholinesterase inhibitor,
rivastigmine, for first line treatment of cognitive symptoms and
visual hallucinations. Physiotherapy was started for her
coexistent polyneuropathy symptoms, although frank
parkinsonian motor features were mild except for syncopal
attacks. Ongoing coordinated review was organised between
the general practitioner and secondary care teams.
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Consent was obtained from the patient and her husband. The husband
read the article to the patient and both were happy with its content. LP
assessed the patient as having capacity at the time of reading the article
to comprehend and consider its contents as pertaining to her medical
history and provide both verbal and written consent for its publication.
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